Cargando…

Prognostic Utility of FBLN2 Expression in Patients With Urothelial Carcinoma

Background: Abnormal extracellular matrix (ECM) remodeling plays an essential role in urothelial carcinoma (UC) invasiveness and metastasis. Focusing on the ECM structural constituent (GO: 0005201), we recognized a significant upregulation of the fibulin 2 gene (FBLN2) during UC progression in a pub...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wei-Ming, Chan, Ti-Chun, Huang, Steven Kuan-Hua, Wu, Wen-Jeng, Ke, Hung-Lung, Liang, Peir-In, Wei, Yu-Ching, Shiue, Yow-Ling, Li, Chien-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659889/
https://www.ncbi.nlm.nih.gov/pubmed/33194662
http://dx.doi.org/10.3389/fonc.2020.570340
_version_ 1783608891174551552
author Li, Wei-Ming
Chan, Ti-Chun
Huang, Steven Kuan-Hua
Wu, Wen-Jeng
Ke, Hung-Lung
Liang, Peir-In
Wei, Yu-Ching
Shiue, Yow-Ling
Li, Chien-Feng
author_facet Li, Wei-Ming
Chan, Ti-Chun
Huang, Steven Kuan-Hua
Wu, Wen-Jeng
Ke, Hung-Lung
Liang, Peir-In
Wei, Yu-Ching
Shiue, Yow-Ling
Li, Chien-Feng
author_sort Li, Wei-Ming
collection PubMed
description Background: Abnormal extracellular matrix (ECM) remodeling plays an essential role in urothelial carcinoma (UC) invasiveness and metastasis. Focusing on the ECM structural constituent (GO: 0005201), we recognized a significant upregulation of the fibulin 2 gene (FBLN2) during UC progression in a published UC transcriptome (GSE31684). Thus, we aimed to investigate the roles of FBLN2 expression and its prognostic value in upper urinary tract UC (UTUC) and urinary bladder UC (UBUC) in our large, well-characterized cohort. Patients and Methods: Clinicopathological data and formalin-fixed paraffin-embedded UC tissues were analyzed retrospectively. We determined FBLN2 expression using immunohistochemical staining assessed by H-scores. FBLN2 expression correlated with clinicopathological features and patient outcomes, including metastasis-free survival (MFS) and disease-specific survival (DSS). Statistical analyses were performed using Pearson's chi-square test, Kaplan–Meier estimates of DSS and MFS, and the Cox proportional hazards model. We used Ingenuity Pathway Analysis (IPA) to clarify the functional significance of dysregulated FBLN2 in UC. Results: Data from 295 UBUC and 340 UTUC patients were available for the final evaluation. Pearson's chi-square test showed that high FBLN2 immunoexpression significantly correlated with adverse pathologic variables, such as advanced pathologic tumor stage, high histological grade, perineural invasion, vascular invasion, lymph node metastasis, and increased mitotic rate (all p < 0.05). Kaplan–Meier analysis demonstrated associations of high FBLN2 expression with worse DSS (p < 0.001) and MFS (p < 0.001). Furthermore, multivariate analysis identified high FBLN2 expression as an independent predictive risk factor for DSS [hazard ratio (HR) in UBUC, 2.306, p = 0.014; in UTUC, 2.561, p = 0.012] and MFS (HR in UBUC, 2.493, p = 0.001; in UTUC, 2.837, p = 0.001). IPA demonstrated that multiple signaling pathways were enriched, including the oxidative phosphorylation, mitochondrial dysfunction, and regulation of the epithelial–mesenchymal transition pathways. Conclusion: High FBLN2 expression was associated with adverse pathologic features and worse oncological outcomes and may serve as a prognostic biomarker for UC.
format Online
Article
Text
id pubmed-7659889
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76598892020-11-13 Prognostic Utility of FBLN2 Expression in Patients With Urothelial Carcinoma Li, Wei-Ming Chan, Ti-Chun Huang, Steven Kuan-Hua Wu, Wen-Jeng Ke, Hung-Lung Liang, Peir-In Wei, Yu-Ching Shiue, Yow-Ling Li, Chien-Feng Front Oncol Oncology Background: Abnormal extracellular matrix (ECM) remodeling plays an essential role in urothelial carcinoma (UC) invasiveness and metastasis. Focusing on the ECM structural constituent (GO: 0005201), we recognized a significant upregulation of the fibulin 2 gene (FBLN2) during UC progression in a published UC transcriptome (GSE31684). Thus, we aimed to investigate the roles of FBLN2 expression and its prognostic value in upper urinary tract UC (UTUC) and urinary bladder UC (UBUC) in our large, well-characterized cohort. Patients and Methods: Clinicopathological data and formalin-fixed paraffin-embedded UC tissues were analyzed retrospectively. We determined FBLN2 expression using immunohistochemical staining assessed by H-scores. FBLN2 expression correlated with clinicopathological features and patient outcomes, including metastasis-free survival (MFS) and disease-specific survival (DSS). Statistical analyses were performed using Pearson's chi-square test, Kaplan–Meier estimates of DSS and MFS, and the Cox proportional hazards model. We used Ingenuity Pathway Analysis (IPA) to clarify the functional significance of dysregulated FBLN2 in UC. Results: Data from 295 UBUC and 340 UTUC patients were available for the final evaluation. Pearson's chi-square test showed that high FBLN2 immunoexpression significantly correlated with adverse pathologic variables, such as advanced pathologic tumor stage, high histological grade, perineural invasion, vascular invasion, lymph node metastasis, and increased mitotic rate (all p < 0.05). Kaplan–Meier analysis demonstrated associations of high FBLN2 expression with worse DSS (p < 0.001) and MFS (p < 0.001). Furthermore, multivariate analysis identified high FBLN2 expression as an independent predictive risk factor for DSS [hazard ratio (HR) in UBUC, 2.306, p = 0.014; in UTUC, 2.561, p = 0.012] and MFS (HR in UBUC, 2.493, p = 0.001; in UTUC, 2.837, p = 0.001). IPA demonstrated that multiple signaling pathways were enriched, including the oxidative phosphorylation, mitochondrial dysfunction, and regulation of the epithelial–mesenchymal transition pathways. Conclusion: High FBLN2 expression was associated with adverse pathologic features and worse oncological outcomes and may serve as a prognostic biomarker for UC. Frontiers Media S.A. 2020-10-29 /pmc/articles/PMC7659889/ /pubmed/33194662 http://dx.doi.org/10.3389/fonc.2020.570340 Text en Copyright © 2020 Li, Chan, Huang, Wu, Ke, Liang, Wei, Shiue and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Wei-Ming
Chan, Ti-Chun
Huang, Steven Kuan-Hua
Wu, Wen-Jeng
Ke, Hung-Lung
Liang, Peir-In
Wei, Yu-Ching
Shiue, Yow-Ling
Li, Chien-Feng
Prognostic Utility of FBLN2 Expression in Patients With Urothelial Carcinoma
title Prognostic Utility of FBLN2 Expression in Patients With Urothelial Carcinoma
title_full Prognostic Utility of FBLN2 Expression in Patients With Urothelial Carcinoma
title_fullStr Prognostic Utility of FBLN2 Expression in Patients With Urothelial Carcinoma
title_full_unstemmed Prognostic Utility of FBLN2 Expression in Patients With Urothelial Carcinoma
title_short Prognostic Utility of FBLN2 Expression in Patients With Urothelial Carcinoma
title_sort prognostic utility of fbln2 expression in patients with urothelial carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659889/
https://www.ncbi.nlm.nih.gov/pubmed/33194662
http://dx.doi.org/10.3389/fonc.2020.570340
work_keys_str_mv AT liweiming prognosticutilityoffbln2expressioninpatientswithurothelialcarcinoma
AT chantichun prognosticutilityoffbln2expressioninpatientswithurothelialcarcinoma
AT huangstevenkuanhua prognosticutilityoffbln2expressioninpatientswithurothelialcarcinoma
AT wuwenjeng prognosticutilityoffbln2expressioninpatientswithurothelialcarcinoma
AT kehunglung prognosticutilityoffbln2expressioninpatientswithurothelialcarcinoma
AT liangpeirin prognosticutilityoffbln2expressioninpatientswithurothelialcarcinoma
AT weiyuching prognosticutilityoffbln2expressioninpatientswithurothelialcarcinoma
AT shiueyowling prognosticutilityoffbln2expressioninpatientswithurothelialcarcinoma
AT lichienfeng prognosticutilityoffbln2expressioninpatientswithurothelialcarcinoma